XML 46 R24.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Revenue from Significant Partners | Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
| Year ended December 31,
| 2023 |  | 2022 |  | 2021
Partner A | 33% |  | 45% |  | 47%
Partner B | 20% |  | 16% |  | 12%
Partner C | 10% |  | <10% |  | <10%
Schedule of Disaggregation of Revenue | Royalty revenue for 2023, 2022 and 2021 for continuing operations are reported as below (in thousands):
|  | Year ended December 31,
|  | 2023 |  | 2022 |  | 2021
Kyprolis |  | $ | 35,640 |  |  | $ | 30,116 |  |  | $ | 27,472 |
Evomela |  | 10,212 |  |  | 10,197 |  |  | 10,079 |
Teriparatide injection |  | 11,061 |  |  | 15,785 |  |  | 5,260 |
Rylaze |  | 13,520 |  |  | 8,796 |  |  | 2,420 |
Other |  | 13,477 |  |  | 7,633 |  |  | 3,696 |
|  | $ | 83,910 |  |  | $ | 72,527 |  |  | $ | 48,927 |
The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):
|  | Year ended December 31,
|  | 2023 |  | 2022 |  | 2021
Captisol |  |  |  |  |  |
Captisol - Core |  | $ | 28,372 |  |  | $ | 16,429 |  |  | $ | 23,423 |
Captisol - COVID(a) |  | — |  |  | 88,066 |  |  | 140,827 |
|  | $ | 28,372 |  |  | $ | 104,495 |  |  | $ | 164,250 |
Contract |  |  |  |  |  |
Service Revenue |  | $ | 615 |  |  | $ | 1,117 |  |  | $ | 3,737 |
License Fees |  | 217 |  |  | 2,849 |  |  | 634 |
Milestone |  | 16,800 |  |  | 9,150 |  |  | 17,584 |
Other |  | 1,400 |  |  | 6,107 |  |  | 6,412 |
|  | $ | 19,032 |  |  | $ | 19,223 |  |  | $ | 28,367 |
(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.
Schedule of Computation of Basic and Diluted Net Income (Loss) per Share | The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):
| Year Ended December 31,
| 2023 |  | 2022 |  | 2021
Weighted average shares outstanding: | 17,298 |  |  | 16,868 |  |  | 16,630 |
Dilutive potential common shares: |  |  |  |  |
Restricted stock | 85 |  |  | — |  |  | 96 |
Stock options | 255 |  |  | — |  |  | 520 |
2023 Convertible Senior Notes | 119 |  |  | — |  |  | — |
Shares used to compute diluted income per share | 17,757 |  |  | 16,868 |  |  | 17,246 |
Potentially dilutive shares excluded from calculation due to anti-dilutive effect | 4,357 |  |  | 6,241 |  |  | 4,793 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration